GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

ustekinumab   Click here for help

GtoPdb Ligand ID: 6885

Synonyms: CNTO-1275 | L04AC05 | Stelara® | TT-20
Approved drug Immunopharmacology Ligand
ustekinumab is an approved drug (FDA (2009), EMA (2009))
Compound class: Antibody
Comment: Ustekinumab suppresses the immunomodulatory actions of both IL-12 and IL-23 on T-cell sub-populations. It binds to the common p40 subunit (IL12B) shared by these cytokines.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

Biosimilars:
NameTrade nameCompanyApprovalsIndications
ustekinumab-auub; ABP 654Wezlana; WezenlaAmgen2023 FDA, 2024 EMAAs per reference agent; Interchangeable with reference agent
ustekinumab-aekn; AVT04Selarsdi; Uzpruvo; UsgenaAlvotech/Teva Pharmaceuticals/STADA Arzneimittel2024 FDA & EMAAs per reference agent
ustekinumab-ttwe; SB17Pyzchiva; Epyztek; EksunbiSandoz/Samsung Bioepis2024 FDA, EMA and S. Korea MFDSAs per reference agent; Interchangeable with reference agent*
ustekinumab; CT-P43SteQeymaCelltrion2024 EMAAs per reference agent
ustekinumab-aauz; FYB202Otulfi; Fymskina Fresenius Kabi/Formycon 2024 EMA & FDAAs per reference agent; available as subcutaneous and intravenous formulations
ustekinumab-srlf; DMB-3115Imuldosa/AbsimkyAccord BioPharma/Intas Pharmaceuticals2024 EMA & FDAAs per reference agent
ustekinumab-kfce; Bmab1200Yesintek Biocon Biologics2024 FDA, 2025 EMAAs per reference agent
ustekinumab-hmny; BAT2206StarjemzaBio-Thera Solutions/Hikma Pharmaceuticals2025 FDAAs per reference agent
biosimilar ustekinumabUsrenty; YesintekBiosimilar Collaborations Ireland/Biocon Biologics2025 EMAAs per reference agent
biosimilar ustekinumabUsymroGedeon Richter2025 EMAAs per reference agent
biosimilar ustekinumabQoyvolmaCelltrion 2025 EMAAs per reference agent
biosimilar ustekinumabUsgenaStada Arzneimittel 2025 EMAAs per reference agent

*After expiry of the period of exclusivity for the first interchangeable biosimilar product.
References
1. Giles-Komar J, Knight DM, Peritt D, Scallon B, Shealy D. (2005)
Also an IL-12 anti-idiotype antibody to the antibody.
Patent number: US6902734. Assignee: Centocor, Inc.. Priority date: 07/08/2000. Publication date: 07/06/2005.
2. Sands BE, Sandborn WJ, Panaccione R, O'Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G et al.. (2019)
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
N Engl J Med, 381 (13): 1201-1214. [PMID:31553833]
3. Zhou L, Wang Y, Wan Q, Wu F, Barbon J, Dunstan R, Gauld S, Konrad M, Leys L, McCarthy R et al.. (2021)
A non-clinical comparative study of IL-23 antibodies in psoriasis.
MAbs, 13 (1): 1964420. [PMID:34460338]